MaxCyte and Ori Biotech's New Collaboration
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) and Ori Biotech have forged a strategic partnership aimed at enhancing the manufacturing efficiency of cellular therapies. This collaboration is an exciting opportunity for the development of next-generation cell therapies, which are crucial for treating various diseases.
Combining Innovative Technologies
The partnership leverages MaxCyte's ExPERT™ platform together with Ori's cutting-edge IRO™ platform, which is designed to revolutionize how cell therapies are manufactured. With MaxCyte’s advanced Flow Electroporation technology, renowned for its high-efficiency transfection capabilities, and Ori's IRO platform, which automates cell culture processes, this collaboration promises to generate more consistent results in cell therapy production.
Key Objectives of the Partnership
One primary objective of this collaboration is to evaluate how Ori’s IRO platform can streamline the manufacturing timelines and optimize yields of MaxCyte-engineered T cells. As part of this initiative, CD19 CAR expression via CRISPR in activated T cells will be used as a model for initial testing, showing the dedication to innovation that both companies share.
Enhancing Scalability and Efficiency
MaxCyte's platform is known for its remarkable flexibility and capacity to transfect cells at a clinical scale, making it compatible with various upstream and downstream processes in cell therapy workflows. Ori’s IRO platform further enhances this capability through automated fluid handling and a customizable tubeless sterile connection system, collectively facilitating the efficient production of gene-edited T cells.
Comments from Leadership
Maher Masoud, the President and CEO of MaxCyte, expressed enthusiasm about the collaboration, stating, "This partnership underscores our commitment to equipping therapy developers with the necessary tools to meet the evolving needs of cell therapy manufacturing. Our goal is to accelerate the delivery of groundbreaking treatments to patients." Similarly, Jason C. Foster, CEO of Ori Biotech, remarked that this collaboration represents a commitment to address significant challenges in the field, promoting greater access to cell therapies.
Commitment to Innovation
Both companies are focused on facilitating seamless transitions from research to commercialization, ensuring that advanced therapies can reach patients who need them. Their shared vision of enhancing manufacturing standards reflects a desire to improve the global landscape of cell and gene therapies.
About MaxCyte
MaxCyte is dedicated to advancing cell engineering through innovative technologies. With over 25 years of experience, the company aims to enable safer and more effective treatments by providing essential tools and expertise in cell therapy development. Learn more at maxcyte.com.
About Ori Biotech
Ori Biotech, with a base in London and Philadelphia, specializes in manufacturing technology aimed at making cell and gene therapies more accessible. Their automated platform, IRO™, seeks to enhance both the quality of cell products and the overall efficiency of therapy manufacturing.
Frequently Asked Questions
What is the purpose of the collaboration between MaxCyte and Ori Biotech?
The collaboration aims to enhance manufacturing efficiency and scalability in cell therapy production, providing advanced solutions for therapy developers.
What technologies are involved in this partnership?
The partnership combines MaxCyte's ExPERT™ platform and Flow Electroporation technology with Ori Biotech's IRO™ manufacturing platform.
Why is the IRO platform significant?
The IRO platform automates key processes in cell therapy manufacturing, improving quality, throughput, and reducing costs.
How will this collaboration impact patients?
This collaboration aims to accelerate the development and availability of cell therapies, making transformative treatments more accessible to patients worldwide.
What are MaxCyte’s main focuses?
MaxCyte focuses on providing innovative technologies that enhance the development and commercialization of next-generation cell therapies, ensuring effective patient treatments.
